These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25758972)

  • 1. [Is the "polypill" in cardiovascular prevention an option].
    Flatz A; Renard D; von Elm E
    Praxis (Bern 1994); 2015 Mar; 104(6):305-6. PubMed ID: 25758972
    [No Abstract]   [Full Text] [Related]  

  • 2. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
    Sanz G; Fuster V
    Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Health and longevity by one tablet daily. Fiction and hard facts on the polypill].
    Holzgreve H
    MMW Fortschr Med; 2014 Jan; 156(1):55-7. PubMed ID: 24930311
    [No Abstract]   [Full Text] [Related]  

  • 5. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polypill: a potential global solution to cardiovascular disease.
    Nguyen C; Cheng-Lai A
    Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could the polypill improve adherence? The patient perspective.
    Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
    J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polypill: quo vadis?
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypill Trials for Stroke Prevention-Main Results, Critical Appraisal, and Implications for US Population.
    Ibraheem M; Goldstein LB
    Curr Neurol Neurosci Rep; 2020 Apr; 20(5):10. PubMed ID: 32296941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. News of the polypill.
    Marshall T
    BMJ; 2008 Oct; 337():a2160. PubMed ID: 18936068
    [No Abstract]   [Full Text] [Related]  

  • 11. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
    Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
    BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAA- a further step towards a moratorium for aspirin in the primary prevention.
    Minar E
    Vasa; 2010 May; 39(2):119-122. PubMed ID: 20521434
    [No Abstract]   [Full Text] [Related]  

  • 13. [Can cardiovascular diseases be reduced over 80% by a "superpill"? Review on the epidemiological study from Wald and Law, 2003].
    Wink K; Otte A
    MMW Fortschr Med; 2008 Jan; 149 Suppl 4():148-52. PubMed ID: 18402239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.
    Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polypill in the primary prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Fundam Clin Pharmacol; 2010 Feb; 24(1):29-35. PubMed ID: 20002198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preventive polypill--much promise, insufficient evidence.
    Reddy KS
    N Engl J Med; 2007 Jan; 356(3):212. PubMed ID: 17229947
    [No Abstract]   [Full Text] [Related]  

  • 18. The cardiovascular polypill: clinical data and ongoing studies.
    Castellano JM; Bueno H; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL; Baron-Esquivias G; Galve E; Lidón RM; Garcia-Moll FX; Sánchez PL; Suárez C; Millán J; Pallares V; Alemán JJ; Egocheaga I
    Med Clin (Barc); 2017 Feb; 148(3):139.e1-139.e15. PubMed ID: 27993410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The polypill strategy in cardiovascular disease prevention: It's time for its implementation.
    Di Fusco SA; Aquilani S; Spinelli A; Alonzo A; Matteucci A; Castello L; Imperoli G; Colivicchi F
    Prog Cardiovasc Dis; 2023; 79():37-40. PubMed ID: 36931543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.